New hope for indian men with advanced prostate cancer: enzalutamide under study

NCT ID NCT03641560

Completed Disease control Sponsor: Astellas Pharma Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the safety and effectiveness of enzalutamide (Xtandi) in 52 Indian men with metastatic castration-resistant prostate cancer that had worsened after chemotherapy. Participants took enzalutamide daily while continuing hormone therapy. The main goal was to see how many experienced side effects, and researchers also measured PSA levels to gauge response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enzalutamide (Xtandi)
What this could lead to: If successful, this could confirm that enzalutamide is safe and effective for Indian patients with advanced prostate cancer, offering a treatment option after chemotherapy.
What could go wrong: This is a small, single-arm study with no placebo group, so results may not be generalizable. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Site IN00001

Pune, India
Site IN00002

Ahmedabad, India
Site IN00003

Nashik, India
Site IN00004

Hubli, India
Site IN00007

Nashik, India
Site IN00008

Kolkata, India
Site IN00010

New Delhi, India
Site IN00011

Surat, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.